LAVA therapeutics B.V.
γδ T cell engager platform

- We create and develop γδ (gamma delta) T cell engaging bispecific antibodies for the treatment of cancer
  - LAVA's technology specifically targets the Vγ9Vδ2 T cell subset
  - Vγ9Vδ2 T-cells were chosen because they represent a sizeable, relatively homogeneous, proinflammatory T cell subset present in the blood and TILs, and which associates with patient survival for a wide range of solid and hematological cancers
  - The potential and safety of γδ T cells has been shown in the clinic
- Our γδ T cell engagers are designed to maximize the therapeutic window and thereby unlock the full potential of T cell engager therapy:
  - Avoids activation of immunosuppressive cells which can dampen the response
  - Shows preferential killing of cancer cells, whilst leaving healthy cells relatively unharmed
  - Avoids T cell exhaustion, as γδ T cells only become activated once the bispecific antibody also binds the tumor associated antigen
  - Takes advantage of the relatively low expression of inhibitory immune checkpoint molecules on Vγ9Vδ2 T cells



LAVA-051: humanized CD1d-Vδ2 bispecific VHH

Dual activation of iNKT and Vγ9Vδ2-T cells





Vδ2-VHH:
activation of Vγ9Vδ2-T (upon bispecific interaction)

CD1d-VHH:
activation of iNKT cells (upon monospecific binding to CD1d)

LAVA-051: Phase 1 FIH Study Design

Patient Population:

Initial 3+3 design, dose-finding study in 15-42 patients with rrMM and rrCLL

- Diseases can be separated in different cohorts if safety data indicates so during the study
- Initiate separate cohort for AML once MTD/R2PD determined for MM or CLL
- Population comprised of relapsed/ refractory CD1d patients not amenable to standard therapy
- Phase 2a dose expansion in disease-specific cohorts to follow

Cohort	Patient Population	n	Tentative Dose levels of LAVA-051 (µg/patient)[c]
1	CLL, MM	1a	0.45
2	CLL, MM	1a	3
3	CLL, MM	1a	15
4b	CLL, MM	3+3	45
5	CLL, MM	3+3	100
6	CLL, MM	3+3	200
7d	AML	3+3	To be defined

Phase 1 – Eligibility – MM and CLL

	MM	CLL
Disease	Measurable IMWG criteria Documented progression	Measurable iwCLL Symptomatic relapse CD5+CD19+CD23+
Prior therapy	≥3 prior regimens including IMIDs, proteasome inhibitor, anti-CD 38	Failed ≥ 1 line of targeted therapy

Phase I Eligibility Criteria (excerpts)

- Positivity for CD1d expression
- ECOG performance status 0 or 1 (2 only with medical monitor approval)
- Predicted life-expectancy of ≥ 3 months
- Patients with Richter's transformation can be included in Part 1 of the trial but not in Part 2 of the trial
- No active-, uncontrolled- or suspected infection
- No previous treatment with an aminobisphosphonate within 4 weeks prior to initial IMP
- No known, clinically relevant immunodeficiency disorder
- No prior allogeneic bone marrow transplant if patient still has GvHD